430 related articles for article (PubMed ID: 28441902)
1. Nonhuman primates as models for the discovery and development of radiation countermeasures.
Singh VK; Olabisi AO
Expert Opin Drug Discov; 2017 Jul; 12(7):695-709. PubMed ID: 28441902
[TBL] [Abstract][Full Text] [Related]
2. Animal models for acute radiation syndrome drug discovery.
Singh VK; Newman VL; Berg AN; MacVittie TJ
Expert Opin Drug Discov; 2015 May; 10(5):497-517. PubMed ID: 25819367
[TBL] [Abstract][Full Text] [Related]
3. Where are the medical countermeasures against the ARS and DEARE? A current topic relative to an animal model research platform, radiation exposure context, the acute and delayed effects of acute exposure, and the FDA animal rule.
MacVittie TJ
Int J Radiat Biol; 2023; 99(7):994-1008. PubMed ID: 36811500
[TBL] [Abstract][Full Text] [Related]
4. Radiation countermeasure agents: an update (2011-2014).
Singh VK; Newman VL; Romaine PL; Wise SY; Seed TM
Expert Opin Ther Pat; 2014 Nov; 24(11):1229-55. PubMed ID: 25315070
[TBL] [Abstract][Full Text] [Related]
5. A review of radiation countermeasures focusing on injury-specific medicinals and regulatory approval status: part II. Countermeasures for limited indications, internalized radionuclides, emesis, late effects, and agents demonstrating efficacy in large animals with or without FDA IND status.
Singh VK; Garcia M; Seed TM
Int J Radiat Biol; 2017 Sep; 93(9):870-884. PubMed ID: 28657406
[TBL] [Abstract][Full Text] [Related]
6. A review of radiation countermeasures focusing on injury-specific medicinals and regulatory approval status: part I. Radiation sub-syndromes, animal models and FDA-approved countermeasures.
Singh VK; Seed TM
Int J Radiat Biol; 2017 Sep; 93(9):851-869. PubMed ID: 28650707
[TBL] [Abstract][Full Text] [Related]
7. The Hematopoietic Syndrome of the Acute Radiation Syndrome in Rhesus Macaques: A Systematic Review of the Lethal Dose Response Relationship.
MacVittie TJ; Farese AM; Jackson W
Health Phys; 2015 Nov; 109(5):342-66. PubMed ID: 26425897
[TBL] [Abstract][Full Text] [Related]
8. Medical countermeasures for unwanted CBRN exposures: part II radiological and nuclear threats with review of recent countermeasure patents.
Singh VK; Romaine PL; Newman VL; Seed TM
Expert Opin Ther Pat; 2016 Dec; 26(12):1399-1408. PubMed ID: 27610458
[TBL] [Abstract][Full Text] [Related]
9. The efficacy and safety of amifostine for the acute radiation syndrome.
Singh VK; Seed TM
Expert Opin Drug Saf; 2019 Nov; 18(11):1077-1090. PubMed ID: 31526195
[No Abstract] [Full Text] [Related]
10. BIO 300: a promising radiation countermeasure under advanced development for acute radiation syndrome and the delayed effects of acute radiation exposure.
Singh VK; Seed TM
Expert Opin Investig Drugs; 2020 May; 29(5):429-441. PubMed ID: 32450051
[TBL] [Abstract][Full Text] [Related]
11. A Metabolomic and Lipidomic Serum Signature from Nonhuman Primates Administered with a Promising Radiation Countermeasure, Gamma-Tocotrienol.
Cheema AK; Mehta KY; Fatanmi OO; Wise SY; Hinzman CP; Wolff J; Singh VK
Int J Mol Sci; 2017 Dec; 19(1):. PubMed ID: 29283379
[TBL] [Abstract][Full Text] [Related]
12. Radioprotective Efficacy of Gamma-Tocotrienol in Nonhuman Primates.
Singh VK; Kulkarni S; Fatanmi OO; Wise SY; Newman VL; Romaine PL; Hendrickson H; Gulani J; Ghosh SP; Kumar KS; Hauer-Jensen M
Radiat Res; 2016 Mar; 185(3):285-98. PubMed ID: 26930378
[TBL] [Abstract][Full Text] [Related]
13. Biologics as countermeasures for acute radiation syndrome: where are we now?
Singh VK; Romaine PL; Newman VL
Expert Opin Biol Ther; 2015 Apr; 15(4):465-71. PubMed ID: 25416452
[TBL] [Abstract][Full Text] [Related]
14. Drug discovery strategies for acute radiation syndrome.
Singh VK; Seed TM; Olabisi AO
Expert Opin Drug Discov; 2019 Jul; 14(7):701-715. PubMed ID: 31008662
[No Abstract] [Full Text] [Related]
15. γ-Tocotrienol as a Promising Countermeasure for Acute Radiation Syndrome: Current Status.
Singh VK; Hauer-Jensen M
Int J Mol Sci; 2016 May; 17(5):. PubMed ID: 27153057
[TBL] [Abstract][Full Text] [Related]
16. Recent advances in medical countermeasure development against acute radiation exposure based on the US FDA animal rule.
MacVittie TJ; Farese AM
J Radiol Prot; 2021 Nov; 41(4):. PubMed ID: 34433144
[TBL] [Abstract][Full Text] [Related]
17. Effects of Gamma-Tocotrienol on Intestinal Injury in a GI-Specific Acute Radiation Syndrome Model in Nonhuman Primate.
Garg S; Garg TK; Wise SY; Fatanmi OO; Miousse IR; Savenka AV; Basnakian AG; Singh VK; Hauer-Jensen M
Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35563033
[TBL] [Abstract][Full Text] [Related]
18. A Metabolomic Serum Signature from Nonhuman Primates Treated with a Radiation Countermeasure, Gamma-tocotrienol, and Exposed to Ionizing Radiation.
Pannkuk EL; Laiakis EC; Fornace AJ; Fatanmi OO; Singh VK
Health Phys; 2018 Jul; 115(1):3-11. PubMed ID: 29787425
[TBL] [Abstract][Full Text] [Related]
19. Development of gamma-tocotrienol as a radiation medical countermeasure for the acute radiation syndrome: current status and future perspectives.
Singh VK; Seed TM
Expert Opin Investig Drugs; 2023 Jan; 32(1):25-35. PubMed ID: 36655861
[TBL] [Abstract][Full Text] [Related]
20. Acute Radiation Effects, the H-ARS in the Non-human Primate: A Review and New Data for the Cynomolgus Macaque with Reference to the Rhesus Macaque.
Farese AM; Drouet M; Herodin F; Bertho JM; Thrall KD; Authier S; Doyle-Eisele M; MacVittie TJ
Health Phys; 2021 Oct; 121(4):304-330. PubMed ID: 34546214
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
